CO2018004750A2 - Composiciones para inhibir la actividad arginasa - Google Patents
Composiciones para inhibir la actividad arginasaInfo
- Publication number
- CO2018004750A2 CO2018004750A2 CONC2018/0004750A CO2018004750A CO2018004750A2 CO 2018004750 A2 CO2018004750 A2 CO 2018004750A2 CO 2018004750 A CO2018004750 A CO 2018004750A CO 2018004750 A2 CO2018004750 A2 CO 2018004750A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- arginase activity
- inhibit arginase
- compounds
- inhibit
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title abstract 3
- 108700024123 Arginases Proteins 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invención se refiere a una nueva clase de compuestos que exhiben actividad inhibidora de la actividad hacia la arginasa, y composiciones farmacéuticas que comprenden los compuestos de la invención. También se proporcionan en el presente documento los métodos para tratar el cáncer con los inhibidores de arginasa de la invención.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562248632P | 2015-10-30 | 2015-10-30 | |
| US201662281964P | 2016-01-22 | 2016-01-22 | |
| US201662323034P | 2016-04-15 | 2016-04-15 | |
| PCT/US2016/059342 WO2017075363A1 (en) | 2015-10-30 | 2016-10-28 | Compositions and methods for inhibiting arginase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018004750A2 true CO2018004750A2 (es) | 2018-10-31 |
Family
ID=58631120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0004750A CO2018004750A2 (es) | 2015-10-30 | 2018-05-02 | Composiciones para inhibir la actividad arginasa |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10065974B2 (es) |
| EP (3) | EP3693375B1 (es) |
| JP (3) | JP6833844B2 (es) |
| KR (2) | KR20220118559A (es) |
| CN (4) | CN113150015A (es) |
| AU (3) | AU2016343656B2 (es) |
| BR (3) | BR122020022280B1 (es) |
| CA (1) | CA3003271A1 (es) |
| CL (4) | CL2018001134A1 (es) |
| CO (1) | CO2018004750A2 (es) |
| CR (3) | CR20180282A (es) |
| CY (1) | CY1123557T1 (es) |
| DK (2) | DK3368541T3 (es) |
| EA (1) | EA038276B1 (es) |
| EC (1) | ECSP18040250A (es) |
| ES (3) | ES2910928T3 (es) |
| HR (1) | HRP20201046T1 (es) |
| HU (1) | HUE054972T2 (es) |
| IL (3) | IL258731B (es) |
| LT (1) | LT3368541T (es) |
| MA (2) | MA50636A (es) |
| MD (1) | MD3368541T2 (es) |
| MX (1) | MX2018005294A (es) |
| MY (1) | MY201783A (es) |
| NZ (1) | NZ742742A (es) |
| PH (2) | PH12022551082A1 (es) |
| PL (1) | PL3368541T3 (es) |
| PT (1) | PT3368541T (es) |
| RS (1) | RS60695B1 (es) |
| SG (4) | SG10201911402YA (es) |
| SI (1) | SI3368541T1 (es) |
| SM (1) | SMT202000469T1 (es) |
| TW (3) | TWI775556B (es) |
| UA (1) | UA125289C2 (es) |
| WO (1) | WO2017075363A1 (es) |
| ZA (4) | ZA201803556B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| US10065974B2 (en) | 2015-10-30 | 2018-09-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| ES2970715T3 (es) * | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| AU2018265873A1 (en) | 2017-05-12 | 2019-11-28 | Calithera Biosciences, Inc. | Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide |
| CN111491937A (zh) * | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| CR20200418A (es) | 2018-02-17 | 2020-10-27 | Astrazeneca Ab | Inhibidores de orginasa y sus mètodos de uso antecedentes |
| KR102656571B1 (ko) | 2018-03-05 | 2024-04-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 아르기나아제 억제제 |
| US12215116B2 (en) | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| PL3774843T3 (pl) | 2018-03-29 | 2022-11-14 | Molecure Sa | Dipeptydowe pochodne piperydyny |
| WO2019245890A1 (en) | 2018-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| WO2020102646A2 (en) | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| CN109364252B (zh) * | 2018-11-21 | 2021-09-28 | 南京大学 | 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用 |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| EP3917936A4 (en) * | 2019-02-06 | 2022-12-14 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | ALKYBORONIC ACIDS AS ARGINASE INHIBITORS |
| AU2020265828A1 (en) * | 2019-05-02 | 2021-09-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as JAK inhibitors |
| AU2020319132B2 (en) * | 2019-07-23 | 2023-09-07 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| CN110615753A (zh) * | 2019-09-02 | 2019-12-27 | 南京新酶合医药科技有限公司 | 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法 |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| CN118286450A (zh) | 2019-11-12 | 2024-07-05 | 纳米医疗有限公司 | 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法 |
| EP4087583A4 (en) * | 2020-01-07 | 2024-01-24 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| WO2022016195A1 (en) | 2020-07-17 | 2022-01-20 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| JP2025509672A (ja) | 2022-03-17 | 2025-04-11 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としての三環式尿素化合物 |
| US20240190876A1 (en) | 2022-10-21 | 2024-06-13 | Incyte Corporation | Tricyclic Urea Compounds As JAK2 V617F Inhibitors |
| CN121079299A (zh) | 2023-03-13 | 2025-12-05 | 因赛特公司 | 作为激酶抑制剂的双环脲 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| CN100408100C (zh) | 1997-07-29 | 2008-08-06 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| JP2002501892A (ja) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な（−）−ビュープロピオンの薬学的使用 |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| US8512717B2 (en) | 2003-08-07 | 2013-08-20 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20090298912A1 (en) | 2005-07-01 | 2009-12-03 | The Johns Hopkins University | Arginase II: A Target treatment of aging heart and heart failure |
| US20100189544A1 (en) | 2007-07-12 | 2010-07-29 | Sanyo Denki Co., Ltd. | Counter-rotating axial-flow fan |
| KR20150115959A (ko) * | 2007-10-12 | 2015-10-14 | 레솔빅스 파마슈티칼즈, 인코퍼레이티드 | 안과 질환의 치료를 위한 옥실리핀 화합물 |
| MX2010012064A (es) * | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
| JP2012515799A (ja) | 2009-01-26 | 2012-07-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | アルギナーゼ阻害剤および使用方法 |
| MX348422B (es) | 2010-04-22 | 2017-06-12 | Mars Inc | Inhibidores de arginasa y sus aplicaciones terapeuticas. |
| DK2632927T3 (en) * | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| US8894970B2 (en) | 2010-12-31 | 2014-11-25 | Corridor Pharmaceuticals, Inc. | Arginase inhibitors and methods of use thereof |
| CA2852685C (en) | 2011-10-19 | 2019-02-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic application |
| WO2013059587A1 (en) | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| CA2870526C (en) | 2012-04-18 | 2020-05-05 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| EA201590822A1 (ru) * | 2012-11-02 | 2016-01-29 | Фармасайкликс, Инк. | Адъювантная терапия ингибитором киназы семейства tec |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| WO2016153078A1 (en) | 2015-03-20 | 2016-09-29 | Opiyo Sammy Oyoo | Use of suramin and arginase inhibitors in malignant neoplasia |
| US10143699B2 (en) * | 2015-06-23 | 2018-12-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| US10065974B2 (en) | 2015-10-30 | 2018-09-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
-
2016
- 2016-10-28 US US15/337,041 patent/US10065974B2/en active Active
- 2016-10-28 TW TW110129153A patent/TWI775556B/zh not_active IP Right Cessation
- 2016-10-28 SI SI201630892T patent/SI3368541T1/sl unknown
- 2016-10-28 ES ES20165627T patent/ES2910928T3/es active Active
- 2016-10-28 LT LTEP16860883.4T patent/LT3368541T/lt unknown
- 2016-10-28 CA CA3003271A patent/CA3003271A1/en active Pending
- 2016-10-28 RS RS20200836A patent/RS60695B1/sr unknown
- 2016-10-28 MA MA050636A patent/MA50636A/fr unknown
- 2016-10-28 PH PH1/2022/551082A patent/PH12022551082A1/en unknown
- 2016-10-28 PL PL16860883T patent/PL3368541T3/pl unknown
- 2016-10-28 ES ES22150809T patent/ES2991555T3/es active Active
- 2016-10-28 CN CN202110097870.5A patent/CN113150015A/zh active Pending
- 2016-10-28 EP EP20165627.9A patent/EP3693375B1/en active Active
- 2016-10-28 MD MDE20180870T patent/MD3368541T2/ro unknown
- 2016-10-28 SG SG10201911402YA patent/SG10201911402YA/en unknown
- 2016-10-28 CN CN202110099500.5A patent/CN113201002A/zh active Pending
- 2016-10-28 ES ES16860883T patent/ES2808988T3/es active Active
- 2016-10-28 UA UAA201805902A patent/UA125289C2/uk unknown
- 2016-10-28 EP EP22150809.6A patent/EP4011887B1/en active Active
- 2016-10-28 AU AU2016343656A patent/AU2016343656B2/en not_active Ceased
- 2016-10-28 EA EA201891057A patent/EA038276B1/ru unknown
- 2016-10-28 CN CN201680063897.XA patent/CN108271371B/zh active Active
- 2016-10-28 CR CR20180282A patent/CR20180282A/es unknown
- 2016-10-28 SM SM20200469T patent/SMT202000469T1/it unknown
- 2016-10-28 NZ NZ742742A patent/NZ742742A/en not_active IP Right Cessation
- 2016-10-28 PT PT168608834T patent/PT3368541T/pt unknown
- 2016-10-28 TW TW109135297A patent/TWI734630B/zh not_active IP Right Cessation
- 2016-10-28 BR BR122020022280-8A patent/BR122020022280B1/pt active IP Right Grant
- 2016-10-28 SG SG10201911406TA patent/SG10201911406TA/en unknown
- 2016-10-28 SG SG10202003966RA patent/SG10202003966RA/en unknown
- 2016-10-28 EP EP16860883.4A patent/EP3368541B1/en active Active
- 2016-10-28 BR BR112018008746-7A patent/BR112018008746B1/pt not_active IP Right Cessation
- 2016-10-28 DK DK16860883.4T patent/DK3368541T3/da active
- 2016-10-28 WO PCT/US2016/059342 patent/WO2017075363A1/en not_active Ceased
- 2016-10-28 CR CR20210389A patent/CR20210389A/es unknown
- 2016-10-28 SG SG11201802961PA patent/SG11201802961PA/en unknown
- 2016-10-28 TW TW105135189A patent/TWI710565B/zh not_active IP Right Cessation
- 2016-10-28 KR KR1020227028040A patent/KR20220118559A/ko active Pending
- 2016-10-28 JP JP2018522126A patent/JP6833844B2/ja active Active
- 2016-10-28 MY MYPI2018701596A patent/MY201783A/en unknown
- 2016-10-28 MX MX2018005294A patent/MX2018005294A/es unknown
- 2016-10-28 BR BR122020022275-1A patent/BR122020022275B1/pt active IP Right Grant
- 2016-10-28 MA MA43131A patent/MA43131B1/fr unknown
- 2016-10-28 CR CR20210390A patent/CR20210390A/es unknown
- 2016-10-28 KR KR1020187015208A patent/KR102434308B1/ko active Active
- 2016-10-28 DK DK22150809.6T patent/DK4011887T3/da active
- 2016-10-28 HR HRP20201046TT patent/HRP20201046T1/hr unknown
- 2016-10-28 HU HUE16860883A patent/HUE054972T2/hu unknown
- 2016-10-28 CN CN202110099502.4A patent/CN113150016A/zh active Pending
- 2016-10-28 PH PH1/2018/500899A patent/PH12018500899B1/en unknown
-
2018
- 2018-04-16 IL IL258731A patent/IL258731B/en active IP Right Grant
- 2018-04-27 CL CL2018001134A patent/CL2018001134A1/es unknown
- 2018-05-02 CO CONC2018/0004750A patent/CO2018004750A2/es unknown
- 2018-05-28 EC ECIEPI201840250A patent/ECSP18040250A/es unknown
- 2018-05-29 ZA ZA2018/03556A patent/ZA201803556B/en unknown
- 2018-08-10 US US16/101,275 patent/US10851118B2/en not_active Expired - Fee Related
-
2019
- 2019-03-28 CL CL2019000819A patent/CL2019000819A1/es unknown
- 2019-03-28 CL CL2019000821A patent/CL2019000821A1/es unknown
- 2019-03-28 CL CL2019000820A patent/CL2019000820A1/es unknown
- 2019-10-28 ZA ZA2019/07092A patent/ZA201907092B/en unknown
- 2019-10-28 ZA ZA2019/07091A patent/ZA201907091B/en unknown
- 2019-10-28 ZA ZA2019/07093A patent/ZA201907093B/en unknown
-
2020
- 2020-03-23 US US16/827,503 patent/US10844080B2/en active Active
- 2020-08-21 CY CY20201100780T patent/CY1123557T1/el unknown
- 2020-11-12 US US17/096,500 patent/US20210061822A1/en not_active Abandoned
- 2020-12-10 AU AU2020286278A patent/AU2020286278B2/en not_active Ceased
-
2021
- 2021-02-02 JP JP2021014795A patent/JP7032583B2/ja not_active Expired - Fee Related
- 2021-03-15 IL IL281503A patent/IL281503B/en unknown
- 2021-11-18 IL IL288225A patent/IL288225A/en unknown
-
2022
- 2022-02-22 JP JP2022025334A patent/JP2022071010A/ja not_active Withdrawn
- 2022-05-31 AU AU2022203703A patent/AU2022203703A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004750A2 (es) | Composiciones para inhibir la actividad arginasa | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| MX2018013593A (es) | Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1. | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| ECSP17005635A (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CR20150316A (es) | Compuestos y sus métodos de empleo | |
| CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
| MX2017001352A (es) | Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2). | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| MX2017010002A (es) | Terapias de combinacion. | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| MX2019002259A (es) | Inhibicion de la actividad de la olig2. | |
| CR20170498A (es) | 2-tiopirimidinonas | |
| EA202191138A1 (ru) | Композиции и способы для ингибирования активности аргиназы | |
| EA201991517A1 (ru) | Композиции и способы ингибирования активности аргиназы |